Loading clinical trials...

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

VICTORION REAL: An International Prospective Real-world Study to Evaluate the LDL-C changE and Adherence to incLisiran in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT05399992•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.

Detailed Description

Patients will be enrolled over a period of 23 months, and followed for up to 24 months to assess for study outcomes.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participants who are 18 years or older
•2. Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH
•3. Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines
•4. Participants who per physician's criteria need to optimize their LLT
•5. Participants who provide written informed consent to participate in the study
•6. Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation.

Exclusion Criteria

•1. Participants that have received inclisiran previously
•2. Participants participating in a clinical trial with investigational product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)

Locations (40)

Novartis Investigative Site

Feldkirch, Austria

Novartis Investigative Site

Graz, Austria

Novartis Investigative Site

Linz, Austria

Novartis Investigative Site

Sankt Veit im Pongau, Austria

Novartis Investigative Site

Vienna, Austria

Novartis Investigative Site

Vienna, Austria

Novartis Investigative Site

Shenzhen, Guangdong, China

Novartis Investigative Site

Holon, Gush Dan, Israel

Novartis Investigative Site

Petah Tikva, Israel

Novartis Investigative Site

Tel Aviv, Israel

Key Dates

Start Date

September 12, 2022

Primary Completion Date

October 5, 2026

Completion Date

October 5, 2026

Last Updated

February 3, 2026

Enrollment

847

ACTUAL participants

Conditions

Primary HypercholesterolemiaMixed Dyslipidemia

Interventions

Inclisiran

OTHER

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

NCT06314919

Primary HypercholesterolemiaMixed Dyslipidemia

View study

RECRUITINGPHASE1

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

NCT06932705

Mixed Dyslipidemia

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

A Study in Patients With Mixed Dyslipidemia

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)